BRAND NAMES
 MECHANISM OF ACTION
Finasteride is a competitive and specific inhibitor of Type II 5α-reductase. Type II 5α-reductase is an enzyme that converts testosterone to dihydrotestosterone (DHT) in human prostate and hair follicles.
In men with male pattern hair loss (androgenetic alopecia), the balding scalp contains miniaturized hair follicles and increased amounts of DHT compared with hairy scalp. Administration of finasteride decreases scalp and serum DHT concentrations in these men. The relative contributions of these reductions to the treatment effect of finasteride have not been defined. By this mechanism, finasteride appears to interrupt a key factor in the development of androgenetic alopecia in those patients genetically predisposed
- Treatment of MALE pattern hair loss (androgenic alopecia)
- Androgenetic alopecia: 1 mg orally once a day with or without meals. In general, daily use for three months or more is necessary before benefit is observed. Continued use is recommended to sustain benefit, which should be re-evaluated periodically. Withdrawal of treatment leads to reversal of effect within 12 months.
- Hypersensitivity to Finasteride
 WARNINGS AND PRECAUTIONS
- Any confirmed increase from the lowest PSA value while on Finasteride may signal the presence of prostate cancer and should be evaluated.
- 5α-reductase inhibitors may increase the risk of development of high-grade prostate cancer.
 PREGNANCY AND LACTATION
- Pregnancy Category X (US). Finasteride is not indicated for use in women
- Nursing Mothers: Finasteride is not indicated for use in women
 SIDE EFFECTS
The most common adverse reactions, reported in ≥1% of patients treated with Finasteride (1mg) and greater than in patients treated with placebo are: decreased libido, erectile dysfunction and ejaculation disorder.
 RELATED LINKS